

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

NCT04886284

Status	RECRUITING
Phase	Phase 2
Sponsor	Todd C. Lee MD MPH FIDSA
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (6)

- Adult ≥ 18 years old
- S. aureus bacteremia within the past 48 hours:
 - with any unknown MRSA status (in centers with $< 15\%$ prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR
 - which has already been shown to be MSSA
- Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).

... and 1 more (see full listing online)

Exclusion (15)

- Clinical:
 - At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at > 24 hours incubation
 - Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)
 - Known seizure disorder
 - Any receipt of valproic acid

... and 10 more (see full listing online)

Locations (5 total)

Foothills Medical Centre, Calgary, Alberta, Canada
Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital), Hamilton, Ontario, Canada
Niagara Health - St. Catharines site, Saint Catharines, Ontario, Canada

... and 2 more locations